
Results
11
Companies which are more than 50% undervalued based on analyst price target.
11 companies
Daiichi Sankyo Company
Market Cap: JP¥4.7t
Manufactures and sells pharmaceutical products in Japan and internationally.
4568
JP¥2,760.00
7D
5.6%
1Y
-12.9%
GNI Group
Market Cap: JP¥188.1b
Engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States.
2160
JP¥2,858.00
7D
13.5%
1Y
-8.3%
PeptiDream
Market Cap: JP¥132.1b
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
4587
JP¥1,038.50
7D
-2.6%
1Y
-32.1%
Nxera Pharma
Market Cap: JP¥89.8b
Operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
4565
JP¥972.00
7D
-2.9%
1Y
13.7%
SanBio
Market Cap: JP¥83.8b
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States.
4592
JP¥1,053.00
7D
4.5%
1Y
-50.3%
Heartseed
Market Cap: JP¥37.5b
Develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure.
219A
JP¥1,641.00
7D
6.8%
1Y
-40.8%
Healios K.K
Market Cap: JP¥33.8b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥250.00
7D
1.6%
1Y
-40.9%
StemRIM
Market Cap: JP¥19.6b
A biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.
4599
JP¥313.00
7D
0%
1Y
2.3%
Kidswell Bio
Market Cap: JP¥7.7b
Develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan.
4584
JP¥154.00
7D
10.0%
1Y
-32.2%
Noile-Immune Biotech
Market Cap: JP¥5.6b
Researches and develops CAR-T cells for novel cancer immunotherapies.
4893
JP¥128.00
7D
6.7%
1Y
-25.1%
TMS
Market Cap: JP¥4.9b
Engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
4891
JP¥108.00
7D
1.9%
1Y
-32.1%